A phase 1 clinical trial, the results of which were published in the medical journal Lancet on Tuesday, has deemed the dissolvable microneedle flu patch to be “well tolerated” and safe for possible use. Instead of receiving a flu vaccine with the typical prick of a syringe, the petite patch comes equipped with 100 microneedles that deliver a vaccine when pressed onto your arm.
“They’re really small; you can barely see them,” said Dr. Nadine Rouphael, an associate professor at the Emory University School of Medicine and lead author of the trial, which was a collaboration with the Georgia Institute of Technology.
She described the microneedles as minuscule enough to not cause as much pain as a traditional flu shot; however, collectively, they were associated with itchiness at the injection site in the trial.
“We also looked at the efficacy of the vaccine. Is it able to induce a similar immune response to the regular flu shot? And it did, actually,” Rouphael said.
The patch contains the same type of vaccine that would be found in a traditional needle and syringe, but it is placed within tiny needles in the patch instead of being placed in only one large one for a flu shot, she said.
“They are placed on a Band-Aid-like structure, and then that Band-Aid is applied, in this case, to the wrist,” she said. “There is an audible snap that you hear when you apply enough pressure to ensure that the microneedles will actually penetrate the skin. … After few minutes, we remove the patch. By then, those microneedles will be completely dissolved within the skin, along with the vaccine.”
They were impressed by how tiny it was’
For the clinical trial, 100 adult volunteers were vaccinated between June and September 2015 at the Hope Clinic of the Emory Vaccine Center in Atlanta. They were randomly separated into four groups before being treated.
One group received a flu vaccine via the patch, administered by a healthcare worker; another received a flu vaccine via a traditional flu shot; another group received a placebo microneedle patch, administered by a healthcare worker; the fourth group used the patch to self-administer a flu vaccine.
The researchers found that, immediately after vaccination, 96% of adults who received the patch reported in a questionnaire that they felt no pain, whereas 82% of those who received the traditional flu shot reported no pain.
At a 28-day follow up, about 70% of the participants who received the patch vaccine reported in a questionnaire that they’d prefer the microneedle patch vaccination over a traditional flu shot or intranasal vaccination.
When comparing the immune responses to the patch and traditional flu shot among the participants, the researchers found similar results.
“We conclude that influenza vaccination with microneedle patches is well tolerated, well accepted, and results in robust immunological responses, whether administered by healthcare workers or by the participants themselves,” the researchers wrote in the study.
Stephen Morse, professor, and director of the infectious disease epidemiology certificate program at Columbia University’s Mailman School of Public Health, said the side effects associated with the patch surprised him.
Scientists at Georgia Tech originally developed this microneedle patch, which has been tested in animals.
Next, the researchers plan to test the new patch in children as well as with other types of vaccines beyond influenza, Rouphael said.